Viridian Therapeutics Stock Cash And Equivalents
| VRDN Stock | USD 19.62 0.17 0.86% |
Viridian Therapeutics fundamentals help investors to digest information that contributes to Viridian Therapeutics' financial success or failures. It also enables traders to predict the movement of Viridian Stock. The fundamental analysis module provides a way to measure Viridian Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Viridian Therapeutics stock.
Viridian | Cash And Equivalents |
Viridian Therapeutics Company Cash And Equivalents Analysis
Viridian Therapeutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Viridian Therapeutics Cash And Equivalents | 161.21 M |
Most of Viridian Therapeutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Viridian Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Viridian Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Viridian Therapeutics is extremely important. It helps to project a fair market value of Viridian Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Viridian Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Viridian Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Viridian Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Viridian Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Viridian Therapeutics has 161.21 M in Cash And Equivalents. This is 80.36% lower than that of the Biotechnology sector and 63.94% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 94.03% higher than that of the company.
Viridian Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viridian Therapeutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Viridian Therapeutics could also be used in its relative valuation, which is a method of valuing Viridian Therapeutics by comparing valuation metrics of similar companies.Viridian Therapeutics is currently under evaluation in cash and equivalents category among its peers.
Viridian Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Viridian Therapeutics from analyzing Viridian Therapeutics' financial statements. These drivers represent accounts that assess Viridian Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Viridian Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 15.0M | 58.5M | 235.6M | 937.3M | 974.8M | 1.0B | |
| Enterprise Value | (1.5M) | 13.1M | 193.9M | 786.9M | 893.0M | 937.6M |
Viridian Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Viridian Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Viridian Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Viridian Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (970.70) % | ||||
| Current Valuation | 1.01 B | ||||
| Shares Outstanding | 79.21 M | ||||
| Shares Owned By Institutions | 100.00 % | ||||
| Number Of Shares Shorted | 10.02 M | ||||
| Price To Book | 3.00 X | ||||
| Price To Sales | 5,146 X | ||||
| Revenue | 314 K | ||||
| Gross Profit | (99.12 M) | ||||
| EBITDA | (234.56 M) | ||||
| Net Income | (237.73 M) | ||||
| Cash And Equivalents | 161.21 M | ||||
| Cash Per Share | 5.66 X | ||||
| Total Debt | 21.05 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 7.77 X | ||||
| Book Value Per Share | 6.55 X | ||||
| Cash Flow From Operations | (184.17 M) | ||||
| Short Ratio | 12.51 X | ||||
| Earnings Per Share | (4.32) X | ||||
| Target Price | 40.63 | ||||
| Number Of Employees | 94 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 1.55 B | ||||
| Total Asset | 490.42 M | ||||
| Retained Earnings | (725.91 M) | ||||
| Working Capital | 459.84 M | ||||
| Net Asset | 490.42 M |
About Viridian Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viridian Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viridian Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viridian Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Viridian Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viridian Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Viridian Stock
| 0.78 | BACK | IMAC Holdings | PairCorr |
| 0.71 | VALN | Valneva SE ADR Downward Rally | PairCorr |
| 0.51 | NKTX | Nkarta Inc | PairCorr |
| 0.51 | CYRX | Cryoport | PairCorr |
| 0.49 | MTEM | Molecular Templates | PairCorr |
The ability to find closely correlated positions to Viridian Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viridian Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viridian Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viridian Therapeutics to buy it.
The correlation of Viridian Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viridian Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viridian Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viridian Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Viridian Therapeutics Piotroski F Score and Viridian Therapeutics Altman Z Score analysis. To learn how to invest in Viridian Stock, please use our How to Invest in Viridian Therapeutics guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Viridian Therapeutics. If investors know Viridian will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Viridian Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.32) | Revenue Per Share 0.005 | Quarterly Revenue Growth 0.194 | Return On Assets (0.32) | Return On Equity (0.52) |
The market value of Viridian Therapeutics is measured differently than its book value, which is the value of Viridian that is recorded on the company's balance sheet. Investors also form their own opinion of Viridian Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Viridian Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Viridian Therapeutics' market value can be influenced by many factors that don't directly affect Viridian Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Viridian Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Viridian Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Viridian Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.